GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Inari Medical Inc (NAS:NARI) » Definitions » ROE %

NARI (Inari Medical) ROE % : -17.11% (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Inari Medical ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Inari Medical's annualized net income for the quarter that ended in Sep. 2024 was $-73.5 Mil. Inari Medical's average Total Stockholders Equity over the quarter that ended in Sep. 2024 was $429.3 Mil. Therefore, Inari Medical's annualized ROE % for the quarter that ended in Sep. 2024 was -17.11%.

The historical rank and industry rank for Inari Medical's ROE % or its related term are showing as below:

NARI' s ROE % Range Over the Past 10 Years
Min: -17.68   Med: 2.06   Max: 17.12
Current: -17.68

During the past 6 years, Inari Medical's highest ROE % was 17.12%. The lowest was -17.68%. And the median was 2.06%.

NARI's ROE % is ranked worse than
65.71% of 802 companies
in the Medical Devices & Instruments industry
Industry Median: -0.21 vs NARI: -17.68

Inari Medical ROE % Historical Data

The historical data trend for Inari Medical's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inari Medical ROE % Chart

Inari Medical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial - 17.12 4.48 -8.92 -0.37

Inari Medical Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.85 -4.07 -21.23 -28.79 -17.11

Competitive Comparison of Inari Medical's ROE %

For the Medical Devices subindustry, Inari Medical's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inari Medical's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Inari Medical's ROE % distribution charts can be found below:

* The bar in red indicates where Inari Medical's ROE % falls into.



Inari Medical ROE % Calculation

Inari Medical's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-1.636/( (417.002+464.91)/ 2 )
=-1.636/440.956
=-0.37 %

Inari Medical's annualized ROE % for the quarter that ended in Sep. 2024 is calculated as

ROE %=Net Income (Q: Sep. 2024 )/( (Total Stockholders Equity (Q: Jun. 2024 )+Total Stockholders Equity (Q: Sep. 2024 ))/ count )
=-73.468/( (423.809+434.761)/ 2 )
=-73.468/429.285
=-17.11 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2024) net income data. ROE % is displayed in the 30-year financial page.


Inari Medical  (NAS:NARI) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2024 )
=Net Income/Total Stockholders Equity
=-73.468/429.285
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-73.468 / 613.56)*(613.56 / 685.0845)*(685.0845 / 429.285)
=Net Margin %*Asset Turnover*Equity Multiplier
=-11.97 %*0.8956*1.5959
=ROA %*Equity Multiplier
=-10.72 %*1.5959
=-17.11 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2024 )
=Net Income/Total Stockholders Equity
=-73.468/429.285
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-73.468 / -50.688) * (-50.688 / -26.648) * (-26.648 / 613.56) * (613.56 / 685.0845) * (685.0845 / 429.285)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.4494 * 1.9021 * -4.34 % * 0.8956 * 1.5959
=-17.11 %

Note: The net income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Inari Medical ROE % Related Terms

Thank you for viewing the detailed overview of Inari Medical's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Inari Medical Business Description

Traded in Other Exchanges
Address
6001 Oak Canyon, Suite 100, Irvine, CA, USA, 92618
Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from Chronic Venous Disease. Its product portfolio includes; ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTriever System product is used for the treatment of pulmonary embolism, InThrill system to treat small vessel thrombosis, LimFlow system and others. Geographically, the company generates majority of its revenue from United States and rest from International markets.
Executives
Andrew Hykes officer: Chief Operating Officer C/O INARI MEDICAL, INC., 9 PARKER AVENUE, SUITE 100, IRVINE CA 92618
William Hoffman director, officer: President and CEO C/O INARI MEDICAL, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Mitch C. Hill, officer: Chief Financial Officer 1009 TENNYSON DRIVE, SOUTHLAKE TX 76902
Thomas Tu officer: Chief Medical Officer C/O INARI MEDICAL, INC., 9 PARKER AVENUE, SUITE 100, IRVINE CA 92618
Rebecca Chambers director 3052 ORCHARD DR., SAN JOSE CA 95134
Donald B Milder director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Robert Keith Warner director C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Catherine M. Szyman director C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Cynthia L Lucchese director 7966 N. ILLINOIS STREET, INDIANAPOLIS IN 46260
Mead Dana G Jr. director 2750 SAND HILL ROAD, MENLO PARK CA 94025
Jonathan D Root director 2735 SAND HILL ROAD, MENLO PARK CA 94025
Cooperatieve Gilde Healthcare Iv U.a. 10 percent owner NEWTONLANN 51, UTRECHT P7 3508AB
Kirk G. Nielsen director, 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Gilde Healthcare Iv Management B.v. 10 percent owner NEWTONLAAN 91, UTRECHT P7 3584 BP
Gilde Healthcare Holding B.v. 10 percent owner NEWTONLAAN 91, PO BOX 85067, 3508 UTRECHT P7 AB